Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01684826
Other study ID # XCY607-100084
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2012
Est. completion date November 2012

Study information

Verified date March 2022
Source Philips Clinical & Medical Affairs Global
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

ClarityIQ is a novel X-ray imaging technology, that combines advanced real-time image noise reduction algorithms, with state-of-the-art hardware to reduce patient entrance dose significantly. This is realized by anatomy-specific optimization of the full acquisition chain (grid switch, beam filtering, pulse width, spot size, detector and image processing engine) for every clinical task individually. Furthermore, smaller focal spot sizes and shorter pulses are used, which are known to positively influence image quality . The final effect on the clinical image quality is investigated in this study.


Description:

Fluoroscopically guided procedures are associated with a risk of radiation injury to the skin, caused by high peak skin dose. The increasingly complex nature of many of the interventions performed requires the use of significant amounts of radiation for their completion. Of particular relevance to dose reduction concerns are obese patients, for whom additional radiation is often necessary to obtained sufficient diagnostic quality, as well as patients suffering from chronic total coronary occlusions (CTO), for whom long procedures with extended radiation time and contrast usage are common. In order to introduce a dose reduction technology the most important aspect is to validate the diagnostic image information. Philips has developed a new algorithm that is capable to process images with similar image quality but acquired at lower dose.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date November 2012
Est. primary completion date November 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients older than 18 years of age undergoing coronary angiography Exclusion Criteria: - Patients not willing or unable to give consent to participate - Patients already involved in a clinical trial - Patients under the age of 18 - Pregnant women and breastfeeding women - Patients with severe kidney disease (eGFR < 60)

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Angiographic run with new algorithm and low dose (50% dose)
Angiographic run with new algorithm and low dose (50% lower dose compared to Xper)
Angiographic run with predecessor algorithm and dose (100%)
Angiographic run with predecessor algorithm and dose (100% dose)

Locations

Country Name City State
Netherlands Radboud University Nijmegen Medical Center Nijmegen

Sponsors (1)

Lead Sponsor Collaborator
Philips Clinical & Medical Affairs Global

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Other Radiation Dose Measurements: Air Kerma (AK) Percentage of change of ClarityIQ vs. AlluraXper in Air Kerma (AK) calculated by AK/frame. Negative percentage means a reduction in dose for ClarityIQ vs. AlluraXper. Participants were followed for the duration of the procedure
Primary Image Quality Overall proportion where diagnostic image quality of ClarityIQ is scored equal or better compared to AlluraXper by the blinded readers. Reading is performed by simultaneous visual comparison of the image quality of AlluraXper and ClarityIQ by multiple blinded reviewers.The images are presented in a randomized order.
The hypothesis is that the overall proportion where diagnostic image quality of ClarityIQ is scored equal or better is = than 0.80. Combined for all raters, the lower bound of the one-sided 95% CI (lower bound of the two-sided 90% CI)is used.
1 day
Secondary Radiation Dose Measurements: Dose Area Product (DAP) Percentage of change of ClarityIQ vs. AlluraXper in Dose Area Product (DAP) calculated by DAP/frame. Negative percentage means a reduction in dose for ClarityIQ vs. AlluraXper. Participants were followed for the duration of the procedure
See also
  Status Clinical Trial Phase
Recruiting NCT05971407 - The Effect of Chronic Remote Ischaemic Preconditioning on Blood Pressure in Older Adults N/A
Enrolling by invitation NCT03683186 - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension Phase 3
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Recruiting NCT04390672 - Multivessel TALENT N/A
Completed NCT01915368 - Determining Optimal Post-Stroke Exercise (DOSE) N/A
Completed NCT01417910 - Predictors of Post Operative Outcome in Peripheral Vascular Surgical Patients N/A
Terminated NCT00935766 - Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries Phase 3
Unknown status NCT01748383 - The Long-term and Short-term Efficacy and Safety of Transplantation Autologous Bone Marrow Cells (BMCs) in Patients With the First STEMI (ST Segment Elevation Myocardial Infarction) Phase 2
Recruiting NCT05907564 - Aventus Thrombectomy System Pulmonary Embolism Clinical Study N/A
Recruiting NCT03732612 - Inflammation in Vascular Disease
Completed NCT00000614 - Prevention of Recurrent Venous Thromboembolism (PREVENT) Phase 3
Completed NCT00000479 - Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer Phase 3
Completed NCT00000530 - Raynaud's Treatment Study (RTS) Phase 3
Completed NCT00000539 - Arterial Disease Multifactorial Intervention Trial (ADMIT) Phase 3
Completed NCT00000474 - Prevention and Treatment of Hypertension Study (PATHS) Phase 3
Completed NCT00000528 - Trials of Hypertension Prevention (TOHP) Phase 3
Completed NCT00000509 - Potassium and Sodium to Control Blood Pressure in Hypertensives Phase 3
Completed NCT00000501 - Hypertension Prevention Trial (HPT) Feasibility Study Phase 2
Completed NCT00000499 - Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study) Phase 2
Completed NCT04340388 - Contribution of Dolutegravir to Obesity and Cardiovascular Disease Phase 4